Smriti Rajita Kumar1, Sameed Ahmed M Khatana2, David Goldberg3. 1. Department of Internal Medicine, University of Miami Miller School of Medicine, Jackson Memorial Hospital, Miami, Florida. 2. Division of Cardiovascular Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. 3. Division of Digestive Health and Liver Diseases, Department of Medicine, University of Miami Miller School of Medicine, Jackson Memorial Hospital, Miami, Florida. Electronic address: dsgoldberg@med.miami.edu.
Abstract
BACKGROUND & AIMS: The Affordable Care Act provided the opportunity for states to expand Medicaid for low-income individuals. Not all states adopted Medicaid expansion, and the timing of adoption among expansion states varied. Prior studies have shown that Medicaid expansion improved mortality rates for several chronic conditions. Although there are data on the association between Medicaid expansion on insurance type among patients waitlisted for a liver transplant, there are no published data to date on its impact on liver disease-related mortality in the broader population. We therefore sought to evaluate the association between Medicaid expansion and state-level liver disease-related mortality using a quasi-experimental study design. METHODS: We evaluated age-adjusted, state-level, liver disease-related mortality rates using the Centers for Disease Control and Prevention data. We fit multivariable linear regression models that accounted for sociodemographic, clinical, and access-to-care variables at the state level, and a difference-in-difference estimator to evaluate the association between Medicaid expansion and liver disease-related mortality. RESULTS: In multivariable linear regression models, there was a significant association between Medicaid expansion and liver disease-related mortality (P = .02). Medicaid expansion was associated with 8.3 (95% CI, 1.6-15.1) fewer deaths from liver disease per 1,000,000 adult residents per year after Medicaid expansion compared with what would have been expected to occur if those states followed the same trajectory as nonexpansion states. The impact of Medicaid expansion translated to 870 fewer liver-related deaths per year in expansion states (4350 in the postexpansion study period from 2014 to 2018). CONCLUSIONS: These data support the contention that Medicaid expansion has been associated with significantly decreased liver disease-related mortality. Universal Medicaid expansion could further decrease liver disease-related mortality in the United States.
BACKGROUND & AIMS: The Affordable Care Act provided the opportunity for states to expand Medicaid for low-income individuals. Not all states adopted Medicaid expansion, and the timing of adoption among expansion states varied. Prior studies have shown that Medicaid expansion improved mortality rates for several chronic conditions. Although there are data on the association between Medicaid expansion on insurance type among patients waitlisted for a liver transplant, there are no published data to date on its impact on liver disease-related mortality in the broader population. We therefore sought to evaluate the association between Medicaid expansion and state-level liver disease-related mortality using a quasi-experimental study design. METHODS: We evaluated age-adjusted, state-level, liver disease-related mortality rates using the Centers for Disease Control and Prevention data. We fit multivariable linear regression models that accounted for sociodemographic, clinical, and access-to-care variables at the state level, and a difference-in-difference estimator to evaluate the association between Medicaid expansion and liver disease-related mortality. RESULTS: In multivariable linear regression models, there was a significant association between Medicaid expansion and liver disease-related mortality (P = .02). Medicaid expansion was associated with 8.3 (95% CI, 1.6-15.1) fewer deaths from liver disease per 1,000,000 adult residents per year after Medicaid expansion compared with what would have been expected to occur if those states followed the same trajectory as nonexpansion states. The impact of Medicaid expansion translated to 870 fewer liver-related deaths per year in expansion states (4350 in the postexpansion study period from 2014 to 2018). CONCLUSIONS: These data support the contention that Medicaid expansion has been associated with significantly decreased liver disease-related mortality. Universal Medicaid expansion could further decrease liver disease-related mortality in the United States.
Authors: David Goldberg; Ivo C Ditah; Kia Saeian; Mona Lalehzari; Andrew Aronsohn; Emmanuel C Gorospe; Michael Charlton Journal: Gastroenterology Date: 2017-01-11 Impact factor: 22.682
Authors: Vilas Patwardhan; Sonali Paul; Kathleen E Corey; Sameer M Mazhar; James M Richter; Michael Thiim; Raymond T Chung Journal: Dig Dis Sci Date: 2011-07-30 Impact factor: 3.199
Authors: Dmitry Tumin; Eliza W Beal; Khalid Mumtaz; Don Hayes; Joseph D Tobias; Timothy M Pawlik; W Kenneth Washburn; Sylvester M Black Journal: J Am Coll Surg Date: 2017-05-19 Impact factor: 6.113
Authors: Christine Y Lu; Fang Zhang; Nicole Golonski; Caitlin Lupton; Paul Jeffrey; Anita K Wagner Journal: Value Health Date: 2017-11-07 Impact factor: 5.725
Authors: Vincent Lo Re; Charitha Gowda; Paul N Urick; Joshua T Halladay; Amanda Binkley; Dena M Carbonari; Kathryn Battista; Cassandra Peleckis; Jody Gilmore; Jason A Roy; Jalpa A Doshi; Peter P Reese; K Rajender Reddy; Jay R Kostman Journal: Clin Gastroenterol Hepatol Date: 2016-04-05 Impact factor: 11.382
Authors: Xiao Jing Wang; Bijan Borah; Ricardo Rojas; Marielle J Kamath; James Moriarty; Alina M Allen; Patrick S Kamath Journal: Mayo Clin Proc Innov Qual Outcomes Date: 2022-06-11